---
title: 'Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes
  in a multicenter retrospective study'
date: '2023-09-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37738563/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230923180942&v=2.17.9.post6+86293ac
source: Blood
description: In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed/refractory
  LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease
  characteristics, and substantially lower progression-free survival and overall survival,
  compared to the L-MIND registration clinical trial for ...
disable_comments: true
---
In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed/refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared to the L-MIND registration clinical trial for ...